A search listing on comparing tirzepatide and semaglutide as weight loss drugs in 2026. No article text came with it, so details are unclear.
Recap by typeshit. Full story at www.polskieradio.pl.
Weight loss may explain much of the knee benefit, but lab work hints at anti-inflammatory and cartilage effects worth a closer read.
A new GLP-1 described as stronger than current options is being tested in trials, and researchers lay out what people should understand about it.
A SURPASS-4 analysis at ASN Kidney Week 2026 found rapid kidney decline in 5% on tirzepatide versus 13% on insulin glargine, with the biggest gains in high protein groups.
Among 208,970 matched adults with type 2 diabetes, GLP-1 starters had 0.15% new diagnoses versus 0.10% on DPP-4 drugs. Authors call it a signal needing confirmation.
The fitness centre says it knows about reports of peptides being sold or promoted inside the gym and makes clear that isn't allowed.
Nurturher Aesthetics explains why most providers aren't using retatrutide, pointing out that the Lilly drug has no FDA approval yet.
Loading…